A combination of the vasopressin type 2 receptor antagonist tolvaptan and the somatostatin analogue pasireotide synergistically reduces cyst progression in a PKD1 mutant mouse model of autosomal dominant polycystic kidney disease (ADPKD). Both drugs indirectly inhibit adenylyl cyclase 6 activity, leading to a reduction in levels of 3', 5'-cAMP, which are decreased to those of wild-type controls by combination therapy. The dual therapy also results in smaller cystic and fibrotic volume, suggesting that it might be an effective treatment for ADPKD.
References
Hopp, K. et al. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J. Am. Soc. Nephrol. 10.1681/ASN.2013121312
Rights and permissions
About this article
Cite this article
Combination therapy reduces cyst progression in ADPKD. Nat Rev Nephrol 10, 482 (2014). https://doi.org/10.1038/nrneph.2014.130
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.130